Court Opinion

ID: 5175621
Source: CourtListenerOpinion
Date Created: 2022-01-03 17:01:07.901385+00
Date Added: 2024-06-11T08:26:16.819344
License: Public Domain

Case: 21-1262   Document: 64     Page: 1   Filed: 12/29/2021

           NOTE: This order is nonprecedential.

   United States Court of Appeals
       for the Federal Circuit
                 ______________________

   SANOFI-AVENTIS U.S. LLC, SANOFI-AVENTIS
    DEUTSCHLAND GMBH, SANOFI WINTHROP
                 INDUSTRIE,
              Plaintiffs-Appellants

                            v.

      MYLAN GMBH, BIOCON LTD., BIOCON
   RESEARCH LTD., BIOCON SDN.BHD, BIOCON
                      S.A.,
              Defendants-Appellees
             ______________________

                       2021-1262
                 ______________________

     Appeal from the United States District Court for the
 District of New Jersey in No. 2:17-cv-09105-SRC-CLW,
 Judge Stanley R. Chesler.
                 ______________________

                     SUA SPONTE
                 ______________________

   Before DYK, CLEVENGER, and TARANTO, Circuit Judges.
 PER CURIAM.
                       ORDER
Case: 21-1262     Document: 64     Page: 2    Filed: 12/29/2021

 2                     SANOFI-AVENTIS U.S. LLC   v. MYLAN GMBH

      Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland
 GmbH, Sanofi Winthrop Industrie (collectively, “Sanofi”)
 filed a patent infringement suit against Mylan GmbH, Bi-
 ocon Ltd., Biocon Research Ltd., Biocon Sdn.Bhd., and Bi-
 ocon S.A. (collectively, “Mylan”) in the District Court for
 the District of New Jersey asserting Mylan infringed
 claims 21, 22, 25, and 30 of Sanofi’s U.S. Patent No.
 9,526,844 (“the ’844 Patent”). The district court found no
 infringement of the asserted claims and that the asserted
 claims are invalid for lack of written description. Sanofi ap-
 peals.
      We affirmed today in a related appeal, Sanofi-Aventis
 U.S. LLC, et al. v. Mylan GmbH, et al., No. 2020-2068, the
 final written decision by the U.S. Patent Trial and Appeal
 Board in IPR2018-01680 holding that claims 21–30 of the
 ’844 Patent would have been unpatentable as anticipated
 and/or obvious. Accordingly, Sanofi’s appeal from the dis-
 trict court’s ruling is moot.
     IT IS ORDERED THAT:
     Sanofi’s appeal in Appeal No. 2021-1262 is dismissed
 as moot.

                                     FOR THE COURT

  December 29, 2021                  /s/ Peter R. Marksteiner
       Date                          Peter R. Marksteiner
                                     Clerk of Court